No Data
No Data
Open Healthcare (300633): Under pressure from a high base, the growth rate is expected to improve quarterly throughout the year
Guide to this report: 2024Q1's performance is in line with expectations. The growth rate is under pressure under pressure under pressure. As the base decreases quarterly, equipment renewal support, and bidding gradually ease, the company's performance is expected to improve quarter by quarter. Key investment points: Maintain an increase in holdings rating. 2 024
Kaili Healthcare (300633.SZ) announced first-quarter results, net profit of 100 million yuan, a decrease of 27.65%
Kaili Healthcare (300633.SZ) released its report for the first quarter of 2024. The company's revenue was 479 million yuan, an increase of 1.33% over the previous year. Net profit attributable to shareholders of listed companies was 100 million yuan, a year-on-year decrease of 27.65%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 92.22,900 yuan, a year-on-year decrease of 26.55%. Basic earnings per share were $0.2326.
Established Healthcare (300633): 1Q24 revenue grew steadily under a high base
Under the high base, the revenue of 1Q24 companies maintained an upward trend, maintaining that the “buy” rating company 1Q24 achieved revenue of 479 million yuan (yoy +1.3%), and net profit of 100 million yuan (yoy -27.7%)
Express News | Open Medical Talk “EU Launches Medical Device Procurement Market Entry Survey to China”: Waiting for Development
Establishing Healthcare (300633): Multi-line integration, fusion take-off, management quality and efficiency to a new level
The company's 2023 revenue was 2.120 billion yuan (up 20.29% year on year), net profit to mother was 454 million yuan (up 22.28% year on year), and 2023 Q4 revenue was 652 million yuan (up 2 percent year over year)
Open Healthcare (300633): Steady growth in performance, looking forward to the release of new products
Core view The company's annual report results are in line with expectations. Short-term results may be under pressure in the first quarter due to the influence of high base figures and industry policies on bidding. The growth rate is expected to increase in the second half of the year, and the equipment renewal policy is expected to make an incremental contribution to the industry. The company is on ultrasound
No Data